$2.31
+0.05 (+2.21%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where LUNG is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 4 observational · 2 with posted results
Held by 13 tracked-famous managers (PRIMECAP MANAGEMENT CO/CA/, JANE STREET GROUP, LLC, AQR CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, D. E. Shaw & Co., Inc., +8 more) · FINRA short interest 1.4 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 15 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe EmphysemaNCT06035120Converters, responder rateOpen-label · Treatment | Not applicable | Recruiting | Device: AeriSeal System | Emphysema, Pulmonary, Emphysema or COPD | 200 | 2027-06-30 | in 314 d | 2026-03-13 |
| Zephyr Valve Japan Post-Marketing SurveillanceNCT06332885observationalIncidence rate of pneumothorax at 45-days post-Zephyr Valve index procedure. | — | Recruiting | Device: Zephyr Endobronchial Valve | Emphysema, COPD, Severe Emphysema | 140 | 2027-03-31 | in 223 d | 2024-12-13 |
| Zephyr Valve Registry (ZEVR)NCT04186546observationalIncidence Rate of Pneumothorax from Baseline to 45-days post-procedure | — | Active, not recruiting | Device: Zephyr Valve Procedure | Emphysema | 150 | 2026-12-31 | in 133 d | 2025-04-29 |
| Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve InsertionNCT04465461Residual Volume (RV)Open-label · Treatment | Not applicable | Completed | Procedure: Video-assisted thoracoscopic surgery (VATS) fissure completion · Device: Zephyr Valve insertion | Pulmonary Emphysema | 9 | 2024-03-05actual | — | 2025-04-29 |
| Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT)NCT04559464Percentage of subjects converted from a positive collateral ventilation status (CV+) to having little to no collateral ventilation (CV-) in the treated lobe.Open-label · Treatment | Not applicable | Completed | Device: AeriSeal, Zephyr Valves | Emphysema, COPD, Severe Emphysema | 102 | 2023-10-24actual | — | 2024-11-04 |
| Zephyr Etude Post-Inscription (French Registry)NCT04517916observationalForced Expiratory Volume in 1 second (FEV1) | — | Completed | Device: Zephyr Valve | Emphysema or COPD | 155 | 2022-06-22actual | — | 2026-02-18 |
| Post-Market Clinical Evaluation of the Zephyr Valve 5.5-LP EBVNCT04161235observationalTreated Lobar Volume Reduction (TLVR) responders | — | Completed | Device: The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP | Pulmonary Emphysema | 2 | 2021-08-13actual | — | 2023-11-15 |
| Clinical Investigation of a Modified Staged Treatment Algorithm Using the AeriSeal SystemNCT02877459Incidence of Serious Adverse EventsOpen-label · Treatment | Not applicable | Completed | Device: AeriSeal System | Emphysema | 14 | 2017-11-16actual | — | 2019-05-31 |
| Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)NCT01796392results2019-03-05Forced Expiratory Volume in 1-second (FEV1)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: EBV · Other: Optimal Medical Management | Emphysema | 190 | Sep 2017actual | — | 2023-06-15 |
| To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr ValvesNCT02022683Forced Expiratory Volume in 1-second (FEV1) - RespondersRandomized · Open-label · Treatment | Not applicable | Completed | Device: ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves | COPD, Heterogeneous Emphysema | 97 | 2017-01-20actual | — | 2019-07-02 |
| A Study of the Use of Chartis System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR)NCT01101958results2014-01-23Lung Volume ChangeOpen-label · Treatment | Not applicable | Completed | Device: Chartis System, Endobronchial Valve (EBV) Treatment | Emphysema | 96 | Mar 2013actual | — | 2017-05-12 |
| Safety and Feasibility Study of the Chartis SystemNCT00684684Adverse eventsOpen-label · Diagnostic | Phase 1 | Completed | Device: Chartis System | Bronchoscopy | 18 | Nov 2008actual | — | 2009-01-22 |
| Safety and Feasibility Study of the Chartis System With Heterogeneous Emphysema Prior to Endobronchial Lung Volume Reduction (ELVR)NCT00684892Adverse eventsOpen-label · Diagnostic | Phase 1/2 | Completed | Device: Chartis System | Heterogeneous Emphysema | 25 | Nov 2008actual | — | 2009-01-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19